Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42693001.
- Also identified by DOI 10.1002/hed.70459.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. A 55-year-old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5. The patient received 2 cycles of neoadjuvant pembrolizumab prior to laryngectomy. The specimen underwent intraoperative micro-positron emission tomography/computed tomography (micro-PET/CT) imaging. Final pathology demonstrated a pathologic complete response (pCR). On pre-treatment whole body PET/CT, maximum standardized uptake value (SUV<sub>max</sub>) was 21.8 in the tumor and 10.7 (~50%) at the tracheostomy site. Intraoperative micro-PET/CT showed residual uptake in the tumor region (SUV<sub>max</sub> 16.1) and tracheostomy site (SUV<sub>max</sub> 16.9). In this case report of pCR, intraoperative micro-PET/CT demonstrated similar avidity at the primary tumor site compared to the tracheostomy site, highlighting the potential utility of this novel imaging approach in patients receiving neoadjuvant immunotherapy.